WOLVERINE ASSET MANAGEMENT LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 50 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
WOLVERINE ASSET MANAGEMENT LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$2,596,000
-89.9%
3,133,000
-90.5%
0.02%
-88.4%
Q4 2020$25,813,000
-54.2%
33,083,000
-53.0%
0.19%
-62.1%
Q3 2020$56,390,000
+7.4%
70,365,0000.0%0.50%
-4.9%
Q2 2020$52,503,000
-6.2%
70,365,000
+2.2%
0.53%
-35.1%
Q1 2020$55,984,000
+8.8%
68,865,000
+35.7%
0.81%
+36.0%
Q4 2019$51,442,000
+31.2%
50,765,000
+12.0%
0.60%
+20.1%
Q3 2019$39,220,000
+3.2%
45,339,000
+6.3%
0.50%
+0.2%
Q2 2019$37,999,000
+117.2%
42,636,000
+142.3%
0.50%
+107.5%
Q1 2019$17,494,000
+1.0%
17,593,000
-5.3%
0.24%
+14.9%
Q4 2018$17,322,000
-4.4%
18,583,000
+3.5%
0.21%
-1.4%
Q3 2018$18,114,000
+122.6%
17,948,000
+71.1%
0.21%
+134.4%
Q3 2017$8,138,000
-80.4%
10,487,000
-75.3%
0.09%
-82.9%
Q2 2017$41,437,000
+4.8%
42,487,000
+0.4%
0.53%
-14.3%
Q1 2017$39,554,000
+2.9%
42,307,000
-1.0%
0.61%
+23.5%
Q4 2016$38,435,000
-19.4%
42,750,0000.0%0.50%
-30.2%
Q3 2016$47,657,00042,750,0000.71%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2019
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders